You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenzyl alcohol
Accession NumberDB06770
TypeSmall Molecule
GroupsApproved
DescriptionNot Available
Structure
Thumb
Synonyms
(Hydroxymethyl)benzene
Alcoholum benzylicum
Alcool benzylique
Alcoolbenzylique
alpha-Hydroxytoluene
alpha-Toluenol
Aromatic alcohol
Bentalol
Benzalalcohol
Benzalcohol
Benzenecarbinol
Benzenemethanol
Benzoyl alcohol
Benzyl alcohol
Benzylalkohol
Benzylic alcohol
Hydroxymethylbenzene
Phenylcarbinol
Phenylmethanol
Phenylmethyl alcohol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Babys Own Gora Teething Lotlotion25 mgG.T. Fulford Pharmaceuticals1961-12-311998-06-25Canada
Babys Own Teething Gelgel25 mgG.T. Fulford Pharmaceuticals1977-12-311998-06-25Canada
Ulesfialotion50 mg/gtopicalZylera Pharmaceuticals, LLC2014-07-16Not applicableUs
Ulesfialotion50 mg/gtopicalConcordia Pharmaceuticals Inc.2009-05-26Not applicableUs
Ulesfialotion50 mg/gtopicalLachlan Pharmaceuticals2015-08-17Not applicableUs
Ulesfialotion50 mg/gtopicalShionogi Inc.2009-05-26Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Averteaxcream10 mg/gtopicalCamellix, LLC2014-01-01Not applicableUs
Baby's Own Teething Gel - 2.5%gel2.5 %topicalBlock Drug Company (Canada) Ltd.1998-03-022001-03-14Canada
Baby's Own Teething Gel 2.5%gel2.5 %topicalDannorth Laboratories Inc.1990-12-311997-08-12Canada
Zilactin Early Relief Cold Soregel.1 g/gtopicalBlairex Laboratories, Inc.2005-06-30Not applicableUs
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Biochemistry Pain Relief Foot ActivePure Source, Inc.
Cipro HCStat Rx USA
Denture Orajel GelCommerce Pharmaceutics Inc.
Foille OntBlistex Corporation
Itch XBF ASCHER AND CO INC
Itch X GelB.F. Ascher & Company Inc.
Itch-XBF ASCHER AND CO INC
Itch-X GelB.F. Ascher & Company Inc.
IvarestBlistex Inc
Ivy DryIvy Dry, Inc.
Ivy-dry SuperIvy Dry, Inc.
NitrotanCramer Products Inc
Shing-releevTopical Pharmaceuticals Inc.
Thomas Formula No 17Thomas Hair And Scalp Specialists
Thomas Formula No 47Thomas Hair And Scalp Specialists
SaltsNot Available
Categories
UNIILKG8494WBH
CAS number100-51-6
WeightAverage: 108.1378
Monoisotopic: 108.057514878
Chemical FormulaC7H8O
InChI KeyInChIKey=WVDDGKGOMKODPV-UHFFFAOYSA-N
InChI
InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2
IUPAC Name
phenylmethanol
SMILES
OCC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzyl alcohols. These are organic compounds containing the phenylmethanol substructure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzyl alcohols
Direct ParentBenzyl alcohols
Alternative Parents
Substituents
  • Benzyl alcohol
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationUlesfia (benzyl alcohol) lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia Lotion does not have ovicidal activity.
PharmacodynamicsNot Available
Mechanism of actionBenzyl alcohol inhibits lice from closing their respiratory spiracles, allowing the vehicle to obstruct the spiracles and causing the lice to asphyxiate.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
Toxicity1250 mg/kg (rat, oral) LD50 400 mg/kg IPR-RAT LD50 2000 mg/kg SKN-RBT LD50 53 mg/kg IVN-RAT LD50 2500 mg/kg ORL-GPG LD50
Affected organisms
  • Head lice
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9906
Blood Brain Barrier+0.9698
Caco-2 permeable+0.8859
P-glycoprotein substrateNon-substrate0.8373
P-glycoprotein inhibitor INon-inhibitor0.9803
P-glycoprotein inhibitor IINon-inhibitor0.9629
Renal organic cation transporterNon-inhibitor0.8259
CYP450 2C9 substrateNon-substrate0.7995
CYP450 2D6 substrateNon-substrate0.9234
CYP450 3A4 substrateNon-substrate0.8408
CYP450 1A2 substrateInhibitor0.5434
CYP450 2C9 inhibitorNon-inhibitor0.9285
CYP450 2D6 inhibitorNon-inhibitor0.9623
CYP450 2C19 inhibitorNon-inhibitor0.7859
CYP450 3A4 inhibitorNon-inhibitor0.9558
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8458
Ames testNon AMES toxic0.9645
CarcinogenicityNon-carcinogens0.5381
BiodegradationReady biodegradable0.8774
Rat acute toxicity1.9753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8998
hERG inhibition (predictor II)Non-inhibitor0.9625
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Creamtopical10 mg/g
Geltopical2.5 %
Lotion25 mg
Gel25 mg
Suspensionauricular (otic)
Gelbuccal; topical
Ointmenttopical
Geltopical
Spraytopical
Creamtopical
Aerosol, spraytopical
Liquidtopical
Lotiontopical50 mg/g
Geltopical.1 g/g
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5858383 No1997-08-112017-08-11Us
US6139859 No1997-08-112017-08-11Us
US6793931 No2002-07-112022-07-11Us
US7294342 No2004-05-192024-05-19Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point-15..2 °C, 258 K, 5 °F# http://sitem.herts.ac.uk/aeru/footprint/en/Reports/953.htm.
boiling point205.3 °C, 478 K, 402 °F# http://sitem.herts.ac.uk/aeru/footprint/en/Reports/953.htm.
water solubility33 mg/mL, clear, colorless# http://www.chemicalbook.com/ProductChemicalPropertiesCB3852587_EN.htm
logP1.1# http://sitem.herts.ac.uk/aeru/footprint/en/Reports/953.htm.
pKa15.4# http://sitem.herts.ac.uk/aeru/footprint/en/Reports/953.htm.
Predicted Properties
PropertyValueSource
Water Solubility26.8 mg/mLALOGPS
logP1.07ALOGPS
logP1.21ChemAxon
logS-0.61ALOGPS
pKa (Strongest Acidic)15.02ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity32.87 m3·mol-1ChemAxon
Polarizability11.89 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.19 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-00ko-6900000000-a9d668ecd37a1579a6feView in MoNA
GC-MSGC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-0a4i-9500000000-2a82c3dd7c6871f61c34View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-0006-9000000000-ad1762d5292c30b29bbdView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-0006-9000000000-3c8d4c630cf42e3bfd3fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI RMU-7M) , Positivesplash10-056r-9400000000-c4dcb2148958f946cd01View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI RMU-6M) , Positivesplash10-056r-9400000000-e17e577dbe4546313a91View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (JEOL JMS-01-SG-2) , Positivesplash10-056r-9300000000-fb124b56257906cce9f1View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-056r-9400000000-47b3605316c57e02b84fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80B) , Positivesplash10-056r-9400000000-dd0878988e7c2d9a5431View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-0a4i-0900000000-3a71c23796a048eb999cView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0a4i-1900000000-40737e7bdf548d714249View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-0uxr-9100000000-23e82914cfa9372ecafcView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-0a4i-1900000000-17f95f5a398b5850abb2View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0a6r-7900000000-733d283e0916e755a736View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-004i-9000000000-d0c6e5fc39516ee594b4View in MoNA
MSMass Spectrum (Electron Ionization)splash10-056r-9400000000-a8f1fd78fa3f8781f296View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Cornelis Jongsma, Leon H. B. Frijns, Paula A. M. Raven-Donners, “Method for the preparation of a pure alkali metal benzoate and benzyl alcohol.” U.S. Patent US4296245, issued June, 1940.

US4296245
General References
  1. Taylor PM, Chengelis CP, Miller WR, Parker GA, Gleason TR, Cozzi E: Evaluation of propofol containing 2% benzyl alcohol preservative in cats. J Feline Med Surg. 2012 Aug;14(8):516-26. doi: 10.1177/1098612X12440354. Epub 2012 Feb 24. [PubMed:22366290 ]
  2. Novak E, Stubbs SS, Sanborn EC, Eustice RM: The tolerance and safety of intravenously administered benzyl alcohol in methylprednisolone sodium succinate formulations in normal human subjects. Toxicol Appl Pharmacol. 1972 Sep;23(1):54-61. [PubMed:4560999 ]
  3. Meinking TL, Villar ME, Vicaria M, Eyerdam DH, Paquet D, Mertz-Rivera K, Rivera HF, Hiriart J, Reyna S: The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). Pediatr Dermatol. 2010 Jan-Feb;27(1):19-24. doi: 10.1111/j.1525-1470.2009.01059.x. [PubMed:20199404 ]
External Links
ATC CodesP03AX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (1.05 MB)
MSDSDownload (50.6 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Benzyl alcohol.
AbirateroneThe serum concentration of Benzyl alcohol can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Benzyl alcohol.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Benzyl alcohol.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Benzyl alcohol.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Benzyl alcohol.
AlfaxaloneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Benzyl alcohol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Benzyl alcohol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benzyl alcohol.
AmiodaroneThe metabolism of Benzyl alcohol can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Benzyl alcohol.
AmitriptylineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Benzyl alcohol.
AmoxapineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amperozide.
AprepitantThe serum concentration of Benzyl alcohol can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzyl alcohol.
ArtemetherThe metabolism of Benzyl alcohol can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Benzyl alcohol.
AtazanavirThe metabolism of Benzyl alcohol can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Benzyl alcohol can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Azaperone.
AzelastineBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Benzyl alcohol.
AzithromycinThe metabolism of Benzyl alcohol can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Benzyl alcohol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Benzyl alcohol.
BetaxololThe metabolism of Benzyl alcohol can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Benzyl alcohol can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Benzyl alcohol can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Benzyl alcohol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Benzyl alcohol can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
BrimonidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benzyl alcohol.
BrompheniramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benzyl alcohol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Benzyl alcohol.
BupropionThe metabolism of Benzyl alcohol can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzyl alcohol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Benzyl alcohol.
ButacaineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Benzyl alcohol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benzyl alcohol.
CaffeineThe metabolism of Benzyl alcohol can be decreased when combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benzyl alcohol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Benzyl alcohol.
CarisoprodolThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Carisoprodol.
CelecoxibThe metabolism of Benzyl alcohol can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Benzyl alcohol can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Benzyl alcohol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benzyl alcohol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Benzyl alcohol.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Benzyl alcohol.
ChloroquineThe metabolism of Benzyl alcohol can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Chlorphenamine.
ChlorpromazineThe metabolism of Benzyl alcohol can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Benzyl alcohol.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Benzyl alcohol can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Benzyl alcohol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Benzyl alcohol can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Benzyl alcohol.
CitalopramThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Citalopram.
CitalopramThe metabolism of Benzyl alcohol can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Benzyl alcohol can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Benzyl alcohol can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clidinium.
ClobazamThe metabolism of Benzyl alcohol can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Benzyl alcohol.
ClomipramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clomipramine.
ClomipramineThe metabolism of Benzyl alcohol can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clonidine.
ClopidogrelThe metabolism of Benzyl alcohol can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzyl alcohol.
ClotrimazoleThe metabolism of Benzyl alcohol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Benzyl alcohol can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clozapine.
CobicistatThe serum concentration of Benzyl alcohol can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Benzyl alcohol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Benzyl alcohol.
ConivaptanThe serum concentration of Benzyl alcohol can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Benzyl alcohol can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzyl alcohol.
CyclosporineThe metabolism of Benzyl alcohol can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Benzyl alcohol can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Benzyl alcohol can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzyl alcohol.
DapoxetineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dapoxetine.
DarifenacinThe metabolism of Benzyl alcohol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Benzyl alcohol can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Benzyl alcohol can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Benzyl alcohol can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Benzyl alcohol can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Benzyl alcohol.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Benzyl alcohol.
DesipramineThe metabolism of Benzyl alcohol can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Detomidine.
DexamethasoneThe serum concentration of Benzyl alcohol can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Benzyl alcohol.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Benzyl alcohol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benzyl alcohol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Benzyl alcohol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Benzyl alcohol.
DifenoxinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benzyl alcohol.
DihydroergotamineThe metabolism of Benzyl alcohol can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Benzyl alcohol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benzyl alcohol.
DiltiazemThe metabolism of Benzyl alcohol can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Benzyl alcohol can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benzyl alcohol.
DisulfiramThe metabolism of Benzyl alcohol can be decreased when combined with Disulfiram.
DoramectinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Doxepin.
DoxorubicinThe metabolism of Benzyl alcohol can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Benzyl alcohol can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
DoxylamineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
DronedaroneThe metabolism of Benzyl alcohol can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Benzyl alcohol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Benzyl alcohol.
DuloxetineThe metabolism of Benzyl alcohol can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Benzyl alcohol.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Benzyl alcohol.
EfavirenzThe serum concentration of Benzyl alcohol can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Efavirenz.
EliglustatThe metabolism of Benzyl alcohol can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Benzyl alcohol.
EntacaponeThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Entacapone.
EnzalutamideThe serum concentration of Benzyl alcohol can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Benzyl alcohol can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Benzyl alcohol can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Benzyl alcohol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Benzyl alcohol.
EthanolBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Benzyl alcohol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzyl alcohol.
EthosuximideThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Benzyl alcohol.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Benzyl alcohol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Benzyl alcohol.
EtidocaineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzyl alcohol.
EtoperidoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Benzyl alcohol.
EtravirineThe serum concentration of Benzyl alcohol can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Felbamate.
FelodipineThe metabolism of Benzyl alcohol can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Benzyl alcohol.
FenfluramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzyl alcohol.
FexofenadineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Flibanserin.
FluconazoleThe metabolism of Benzyl alcohol can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Benzyl alcohol.
FlunarizineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Benzyl alcohol.
FluoxetineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluoxetine.
FluoxetineThe metabolism of Benzyl alcohol can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzyl alcohol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzyl alcohol.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Benzyl alcohol.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Benzyl alcohol.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluvoxamine.
FluvoxamineThe metabolism of Benzyl alcohol can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Benzyl alcohol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Benzyl alcohol can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Benzyl alcohol.
Fusidic AcidThe serum concentration of Benzyl alcohol can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benzyl alcohol.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Benzyl alcohol.
GemfibrozilThe metabolism of Benzyl alcohol can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Benzyl alcohol.
GuanfacineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Benzyl alcohol.
HaloperidolThe metabolism of Benzyl alcohol can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Benzyl alcohol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Benzyl alcohol.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Benzyl alcohol.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Benzyl alcohol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Benzyl alcohol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzyl alcohol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
HydroxyzineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Hydroxyzine.
IdelalisibThe serum concentration of Benzyl alcohol can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Iloperidone.
ImatinibThe metabolism of Benzyl alcohol can be decreased when combined with Imatinib.
ImipramineThe metabolism of Benzyl alcohol can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Indalpine.
IndinavirThe metabolism of Benzyl alcohol can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Benzyl alcohol can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Benzyl alcohol can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Benzyl alcohol.
IsoniazidThe metabolism of Benzyl alcohol can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Benzyl alcohol can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Benzyl alcohol can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Benzyl alcohol can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Benzyl alcohol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Benzyl alcohol.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Benzyl alcohol.
KetoconazoleThe metabolism of Benzyl alcohol can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lamotrigine.
LapatinibThe metabolism of Benzyl alcohol can be decreased when combined with Lapatinib.
LevetiracetamThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Benzyl alcohol.
LevocabastineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Benzyl alcohol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benzyl alcohol.
LidocaineThe metabolism of Benzyl alcohol can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Benzyl alcohol.
LofentanilThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lofentanil.
LopinavirThe metabolism of Benzyl alcohol can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Benzyl alcohol.
LorcaserinThe metabolism of Benzyl alcohol can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Benzyl alcohol can be decreased when combined with Losartan.
LovastatinThe metabolism of Benzyl alcohol can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Benzyl alcohol.
Lu AA21004The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lu AA21004.
LuliconazoleThe serum concentration of Benzyl alcohol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Benzyl alcohol can be increased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Benzyl alcohol can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Benzyl alcohol.
MelperoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzyl alcohol.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzyl alcohol.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzyl alcohol.
MetaxaloneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Metaxalone.
MethadoneThe metabolism of Benzyl alcohol can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Benzyl alcohol.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Benzyl alcohol.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Benzyl alcohol.
MethocarbamolThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Benzyl alcohol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Benzyl alcohol.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Benzyl alcohol.
MethsuximideThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Benzyl alcohol.
MetoprololThe metabolism of Benzyl alcohol can be decreased when combined with Metoprolol.
MetyrosineBenzyl alcohol may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Benzyl alcohol can be decreased when combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Benzyl alcohol.
MifepristoneThe metabolism of Benzyl alcohol can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
MirabegronThe metabolism of Benzyl alcohol can be decreased when combined with Mirabegron.
MirtazapineBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Benzyl alcohol.
MitotaneThe serum concentration of Benzyl alcohol can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Benzyl alcohol can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Benzyl alcohol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Benzyl alcohol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.
NabiloneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Nabilone.
NafcillinThe serum concentration of Benzyl alcohol can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benzyl alcohol.
NefazodoneThe metabolism of Benzyl alcohol can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Benzyl alcohol can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Benzyl alcohol can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Benzyl alcohol can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Benzyl alcohol can be decreased when combined with Nicardipine.
NicotineThe metabolism of Benzyl alcohol can be decreased when combined with Nicotine.
NilotinibThe metabolism of Benzyl alcohol can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Benzyl alcohol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Benzyl alcohol.
NormethadoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Olanzapine.
OlaparibThe metabolism of Benzyl alcohol can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Benzyl alcohol.
OpiumThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Opium.
OrphenadrineBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Benzyl alcohol.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Benzyl alcohol.
OsimertinibThe serum concentration of Benzyl alcohol can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Benzyl alcohol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Benzyl alcohol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Benzyl alcohol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzyl alcohol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benzyl alcohol.
PalbociclibThe serum concentration of Benzyl alcohol can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benzyl alcohol.
PanobinostatThe metabolism of Benzyl alcohol can be decreased when combined with Panobinostat.
ParaldehydeBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Benzyl alcohol.
ParoxetineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Paroxetine.
ParoxetineThe metabolism of Benzyl alcohol can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Benzyl alcohol can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzyl alcohol.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Benzyl alcohol.
PerampanelThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Benzyl alcohol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Benzyl alcohol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benzyl alcohol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Benzyl alcohol.
PioglitazoneThe metabolism of Benzyl alcohol can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pomalidomide.
PosaconazoleThe metabolism of Benzyl alcohol can be decreased when combined with Posaconazole.
PramipexoleBenzyl alcohol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Benzyl alcohol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Benzyl alcohol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Benzyl alcohol.
PrimidoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Benzyl alcohol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzyl alcohol.
PromazineThe metabolism of Benzyl alcohol can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Benzyl alcohol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Benzyl alcohol.
PropoxycaineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Benzyl alcohol.
QuazepamThe serum concentration of Benzyl alcohol can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzyl alcohol.
QuinidineThe metabolism of Benzyl alcohol can be decreased when combined with Quinidine.
QuinineThe metabolism of Benzyl alcohol can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Benzyl alcohol can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ramelteon.
RanolazineThe metabolism of Benzyl alcohol can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzyl alcohol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzyl alcohol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Benzyl alcohol.
RifabutinThe metabolism of Benzyl alcohol can be increased when combined with Rifabutin.
RifampicinThe metabolism of Benzyl alcohol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Benzyl alcohol can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Benzyl alcohol.
RitonavirThe metabolism of Benzyl alcohol can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Benzyl alcohol can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Romifidine.
RopiniroleBenzyl alcohol may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Benzyl alcohol can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzyl alcohol.
RosiglitazoneThe metabolism of Benzyl alcohol can be decreased when combined with Rosiglitazone.
RotigotineBenzyl alcohol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Benzyl alcohol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Benzyl alcohol.
SaquinavirThe metabolism of Benzyl alcohol can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benzyl alcohol.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Benzyl alcohol.
SertralineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Sertraline.
SertralineThe metabolism of Benzyl alcohol can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benzyl alcohol.
SildenafilThe metabolism of Benzyl alcohol can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Benzyl alcohol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Benzyl alcohol can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Sodium oxybate.
SorafenibThe metabolism of Benzyl alcohol can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Benzyl alcohol can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol.
SulfamethoxazoleThe metabolism of Benzyl alcohol can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Benzyl alcohol can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzyl alcohol.
SuvorexantThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Suvorexant.
TamoxifenThe metabolism of Benzyl alcohol can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptBenzyl alcohol may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TelaprevirThe metabolism of Benzyl alcohol can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Benzyl alcohol can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Benzyl alcohol.
TenofovirThe metabolism of Benzyl alcohol can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Benzyl alcohol can be decreased when combined with Terbinafine.
TeriflunomideThe serum concentration of Benzyl alcohol can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Benzyl alcohol.
ThalidomideBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Benzyl alcohol.
TheophyllineThe metabolism of Benzyl alcohol can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Benzyl alcohol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Benzyl alcohol.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benzyl alcohol.
ThiotepaThe metabolism of Benzyl alcohol can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benzyl alcohol.
TiagabineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tiagabine.
TiclopidineThe metabolism of Benzyl alcohol can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tiletamine.
TipranavirThe metabolism of Benzyl alcohol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tizanidine.
TocilizumabThe serum concentration of Benzyl alcohol can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzyl alcohol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Benzyl alcohol.
TranylcypromineThe metabolism of Benzyl alcohol can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Benzyl alcohol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzyl alcohol.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzyl alcohol.
TrimethoprimThe metabolism of Benzyl alcohol can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Benzyl alcohol.
VemurafenibThe serum concentration of Benzyl alcohol can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Benzyl alcohol can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Benzyl alcohol can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Vilazodone.
VoriconazoleThe metabolism of Benzyl alcohol can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Benzyl alcohol.
ZiconotideThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Zimelidine.
ZiprasidoneThe metabolism of Benzyl alcohol can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Benzyl alcohol.
ZonisamideThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Benzyl alcohol.
ZotepineThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzyl alcohol.
Food InteractionsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T: Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem Pharmacol. 1997 Feb 7;53(3):271-7. [PubMed:9065730 ]
  2. Kim H, Wang RS, Elovaara E, Raunio H, Pelkonen O, Aoyama T, Vainio H, Nakajima T: Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65. [PubMed:9253143 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Furman GM, Silverman DM, Schatz RA: Inhibition of rat lung mixed-function oxidase activity following repeated low-level toluene inhalation: possible role of toluene metabolites. J Toxicol Environ Health A. 1998 Aug 21;54(8):633-45. [PubMed:9726784 ]
  2. Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T: Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem Pharmacol. 1997 Feb 7;53(3):271-7. [PubMed:9065730 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Electron carrier activity
Specific Function:
Not Available
Gene Name:
ALDH2
Uniprot ID:
P05091
Molecular Weight:
56380.93 Da
References
  1. Kawamoto T, Koga M, Murata K, Matsuda S, Kodama Y: Effects of ALDH2, CYP1A1, and CYP2E1 genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans. Toxicol Appl Pharmacol. 1995 Aug;133(2):295-304. [PubMed:7645026 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T: Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem Pharmacol. 1997 Feb 7;53(3):271-7. [PubMed:9065730 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T: Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem Pharmacol. 1997 Feb 7;53(3):271-7. [PubMed:9065730 ]
  2. Kim H, Wang RS, Elovaara E, Raunio H, Pelkonen O, Aoyama T, Vainio H, Nakajima T: Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65. [PubMed:9253143 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T: Toluene metabolism by cDNA-expressed human hepatic cytochrome P450. Biochem Pharmacol. 1997 Feb 7;53(3):271-7. [PubMed:9065730 ]
  2. Lipscomb JC, Barton HA, Tornero-Velez R, Evans MV, Alcasey S, Snawder JE, Laskey J: The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A. 2004 Apr 9;67(7):537-53. [PubMed:15129551 ]
  3. Kim H, Wang RS, Elovaara E, Raunio H, Pelkonen O, Aoyama T, Vainio H, Nakajima T: Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65. [PubMed:9253143 ]
  4. Wang RS, Nakajima T, Park SS, Gelboin HV, Murayama N: Monoclonal antibody-directed assessment of toluene induction of rat hepatic cytochrome P450 isozymes. Biochem Pharmacol. 1993 Aug 3;46(3):413-9. [PubMed:8347164 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Obach RS: Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607. [PubMed:11717179 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Obach RS: Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607. [PubMed:11717179 ]
Comments
comments powered by Disqus
Drug created on September 14, 2010 10:21 / Updated on September 26, 2016 02:13